Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.

Journal of translational medicine - 24 Mar 2024

Li Jiao, Wang Fei, Li Zhen, Feng Jingjing, Men Yi, Han Jinming, Xia Jiangwei, Zhang Chen, Han Yilai, Chen Teng, Zhao Yinan, Zhou Sirui, Da Yuwei, Chai Guoliang, Hao Junwei

Abstract excerpt

BACKGROUND: Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating muscle weakness. Despite the availability of established therapies, the management of MG symptoms remains suboptimal, partially attributed to lack of efficacy or intolerable side-effects. Therefore, new effective drugs are warranted for treatment of MG. METHODS: By employing an analytical framework that combines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibromyalgia and Chronic Fatigue Syndrome Research
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Multiomics

Share to Myasthenia Gravis

Share to Myasthenia Gravis and Thymoma

Share to Polymorphism, Single Nucleotide

Share to Quantitative Trait Loci

Source

Open in PubMed Open full text

Identifiers

PMID: 38521921
DOI: 10.1186/s12967-024-04994-2
PMCID: PMC10960998

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.PMID 38521921Read ↗

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.Semantic proximity Read ↗

Investigating Overlapping Genetic Factors and Novel Causal Genes in Autoimmune Diseases: A Transcriptome‐Wide Association and Multiomics StudySemantic proximity Read ↗

Genetic Architecture of Idiopathic Inflammatory Myopathies From Meta-Analyses.Semantic proximity Read ↗

Identification of drug targets for Sjögren's syndrome: multi-omics Mendelian randomization and colocalization analyses.Semantic proximity Read ↗

Genetic and mechanistic overlap between Alzheimer’s disease and myasthenia gravis: insights into neuro-immune crosstalkSemantic proximity Read ↗

Genetic analyses of inflammatory polyneuropathy and chronic inflammatory demyelinating polyradiculoneuropathy identified candidate genesSemantic proximity Read ↗

CFD+CD14+ monocytes: potential pathogenic subset in myasthenia gravis uncovered by multi-omics integration and machine learning analysis.Semantic proximity Read ↗

Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteinsSemantic proximity Read ↗

Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction.Semantic proximity Read ↗

An integrative multi-omics analysis of 16 autoimmune diseases and cancer outcomes highlights immune-cell regulatory mechanisms and shared genetic architectureSemantic proximity Read ↗

Multi-omics integration prioritizes potential drug targets for multiple sclerosisSemantic proximity Read ↗

Mitochondrial proteins contribute to the pathogenesis of myasthenia gravis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.